Search

Your search keyword '"Pratt, Victoria M."' showing total 3 results
Start Over Author "Pratt, Victoria M." Language undetermined
3 results on '"Pratt, Victoria M."'

1. Additional file 1 of Translating pharmacogenetics from research to routine clinical practice – a survey of the IGNITE Network

Author

Levy, Kenneth D., R. Ryanne Wu, Goto, Daisuke, Ramos, Michelle A., Pratt, Victoria M., J. Kevin Hicks, Madden, Ebony B., Bell, Gillian C., Blake, Kathryn V., Cohen, Michelle, Duong, Benjamin Q., Franciosi, James P., Orlando, Lori A., Kunal Sanghavi, and Ginsburg, Geoffrey S.

Abstract

Additional file 1. (IGNITE Sustainability Survey Tool)

Published
2020
Full Text
View/download PDF

2. Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee

Author

Vassy, Jason L, Stone, Annjanette, Callaghan, John T, Mendes, Margaret, Meyer, Laurence J, Pratt, Victoria M, Przygodzki, Ronald M, Scheuner, Maren T, Wang-Rodriguez, Jessica, Schichman, Steven A, and VHA Clinical Pharmacogenetics Subcommittee

Subjects
Genetics & Heredity, Genetic testing, Genotype, Clinical Sciences, Veterans Health, Glucosephosphate Dehydrogenase, HLA-B15 Antigen, Evidence-based practice, United States, Pharmacogenomic Testing, Clopidogrel, Cytochrome P-450 CYP2C19, VHA Clinical Pharmacogenetics Subcommittee, United States Department of Veterans Affairs, Cytochrome P-450 CYP2D6, Pharmacogenetics, Stevens-Johnson Syndrome, Genetics, Humans, Policymaking, health care economics and organizations, Veterans
Abstract

PurposeThe Veterans Health Administration (VHA) Clinical Pharmacogenetics Subcommittee is charged with making recommendations about whether specific pharmacogenetic tests should be used in healthcare at VHA facilities. We describe a process to inform VHA pharmacogenetic testing policy.MethodsAfter developing consensus definitions of clinical validity and utility, the Subcommittee identified salient drug-gene pairs with potential clinical application in VHA. Members met monthly to discuss each drug-gene pair, the evidence of clinical utility for the associated pharmacogenetic test, and any VHA-specific testing considerations. The Subcommittee classified each test as strongly recommended, recommended, or not routinely recommended before drug initiation.ResultsOf 30 drug-gene pair tests reviewed, the Subcommittee classified 4 (13%) as strongly recommended, including HLA-B*15:02 for carbamazepine-associated Stevens-Johnston syndrome and G6PD for rasburicase-associated hemolytic anemia; 12 (40%) as recommended, including CYP2D6 for codeine toxicity; and 14 (47%) as not routinely recommended, such as CYP2C19 for clopidogrel dosing.ConclusionOnly half of drug-gene pairs with high clinical validity received Subcommittee support for policy promoting their widespread use across VHA. The Subcommittee generally found insufficient evidence of clinical utility or available, effective alternative strategies for the remainders. Continual evidence review and rigorous outcomes research will help promote the translation of pharmacogenetic discovery to healthcare.

Published
2019

3. Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee

Author

Vassy, Jason L, Stone, Annjanette, Callaghan, John T, Mendes, Margaret, Meyer, Laurence J, Pratt, Victoria M, Przygodzki, Ronald M, Scheuner, Maren T, Wang-Rodriguez, Jessica, Schichman, Steven A, and VHA Clinical Pharmacogenetics Subcommittee

Subjects
Genetics & Heredity, Genetic testing, Genotype, Clinical Sciences, Veterans Health, Glucosephosphate Dehydrogenase, HLA-B15 Antigen, Evidence-based practice, United States, Pharmacogenomic Testing, Clopidogrel, Cytochrome P-450 CYP2C19, VHA Clinical Pharmacogenetics Subcommittee, United States Department of Veterans Affairs, Good Health and Well Being, Cytochrome P-450 CYP2D6, Pharmacogenetics, Clinical Research, Stevens-Johnson Syndrome, Genetics, Humans, Policymaking, Patient Safety, health care economics and organizations, Veterans
Abstract

PurposeThe Veterans Health Administration (VHA) Clinical Pharmacogenetics Subcommittee is charged with making recommendations about whether specific pharmacogenetic tests should be used in healthcare at VHA facilities. We describe a process to inform VHA pharmacogenetic testing policy.MethodsAfter developing consensus definitions of clinical validity and utility, the Subcommittee identified salient drug-gene pairs with potential clinical application in VHA. Members met monthly to discuss each drug-gene pair, the evidence of clinical utility for the associated pharmacogenetic test, and any VHA-specific testing considerations. The Subcommittee classified each test as strongly recommended, recommended, or not routinely recommended before drug initiation.ResultsOf 30 drug-gene pair tests reviewed, the Subcommittee classified 4 (13%) as strongly recommended, including HLA-B*15:02 for carbamazepine-associated Stevens-Johnston syndrome and G6PD for rasburicase-associated hemolytic anemia; 12 (40%) as recommended, including CYP2D6 for codeine toxicity; and 14 (47%) as not routinely recommended, such as CYP2C19 for clopidogrel dosing.ConclusionOnly half of drug-gene pairs with high clinical validity received Subcommittee support for policy promoting their widespread use across VHA. The Subcommittee generally found insufficient evidence of clinical utility or available, effective alternative strategies for the remainders. Continual evidence review and rigorous outcomes research will help promote the translation of pharmacogenetic discovery to healthcare.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results